Implantable cardiac device for monitoring diastolic heart failure and method of operation and use thereof

• US 7,526,338 B1
• Filed: 05/23/2005
• Issued: 04/28/2009
• Est. Priority Date: 05/23/2005
• Status: Active Grant

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Inventors: Gill, Jong, Min, Xiaoyi, Bornzin, Gene A.
• Primary Examiner(s): Layno; Carl H
• Assistant Examiner(s): SARCIONE, JESSICA LYNN
• Application Number:
  US11/136,268
• Time in Patent Office: 1,436 Days
• Field of Search: 600/509, 600/513, 600485-486, 600/508, 600/526, 607/23, 607/6, 607/9, 607/17, 607/18, 607/25, 607/28
• US Class Current: 607/18
• CPC Class Codes: A61B 5/0215 by means inserted into the body catheters A61M25/00
• CPC Class Codes: A61N 1/3627 for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
• CPC Class Codes: A61N 1/365 controlled by a physiological parameter, e.g. heart potential evoked response A61N1/371
• CPC Class Codes: A61N 1/36564 controlled by blood pressure
• CPC Class Codes: G16H 20/30 relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
• CPC Class Codes: G16H 50/50 for simulation or modelling of medical disorders

Abstract

An implantable cardiac device is used to measure one or more parameters relating to cardiac activity of a patient'"'"'s heart, from which diastolic heart failure (“DHF”) may be monitored and/or detected. These parameters are used to calculate ventricular isovolumetric relaxation time or a related time value. Heart conditions possibly having an influence on the ventricular isovolumetric relaxation time, other than heart conditions due to reduced compliance, may be detected and used to prevent an incorrect calculation of the ventricular isovolumetric relaxation time. The parameters may be measured and the relaxation time calculated multiple times over a period of time, which enables monitoring of the progression of change in the relaxation time. The relaxation time and the progression of change therein are indicators of DHF.

Claims

1. A method of monitoring a patient for diastolic heart failure with an implanted cardiac device, comprising:

obtaining with the implanted cardiac device a waveform indicative of left ventricular pressure of the patient during an early part of isovolumetric relaxation;

calculating an indication of dispersion of relaxation from the waveform;

calculating a parameter from the waveform that is indicative of diastolic heart failure;

adjusting the parameter as a function of the indication of dispersion;

calculating an indication of diastolic heart failure from the adjusted parameter; and

adjusting a therapeutic action in response to the indication of diastolic heart failure and the indication of dispersion of relaxation.

2. The method of claim 1 wherein calculating a parameter that is an indication of diastolic heart failure from the waveform comprises calculating a time from a first amplitude level of the waveform to a second amplitude level of the waveform less than the first amplitude level.

3. The method of claim 1 wherein calculating an indication of dispersion of relaxation from the waveform comprises calculating slope of the waveform over a fixed period of time from start of isovolumetric relaxation, or a maximum slope of the LV waveform over a particular period of time, or maximum slope of the LV waveform until decline of the LV pressure to a particular value.

4. The method of claim 1 wherein calculating a parameter from the waveform that is indicative of diastolic heart failure comprises calculating the isovolumetric relaxation time.

5. A method of monitoring a patient for diastolic heart failure with an implanted cardiac device, comprising:

obtaining with the implanted cardiac device at least one cardiac signal indicative of cardiac activity of the patient;

calculating from the cardiac signal in the implanted cardiac device a ventricular isovolumetric relaxation time;

obtaining an indication of a heart condition that is capable of influencing the ventricular isovolumetric relaxation time, other than reduced ventricular compliance;

calculating an indication of diastolic heart failure from the ventricular isovolumetric relaxation time and the heart condition indication; and

adjusting a therapeutic action in response to the indication of diastolic heart failure.

6. The method of claim 5 further comprising reporting the ventricular isovolumetric relaxation time to an external device, wherein the heart condition indication is obtained from the external device and the diastolic heart failure calculating step is performed by the external device.

7. The method of claim 5 wherein the heart condition indication and the diastolic heart failure are calculated by the implantable cardiac device.

8. The method of claim 5 further comprising reporting the indication of diastolic heart failure to an external device.

9. The method of claim 5 wherein the cardiac signal obtaining step comprises detecting left ventricle pressure of the patient with the cardiac device.

10. The method of claim 5 wherein the diastolic heart failure indication calculating step comprises evaluating diastolic heart failure from a prior progression of change in relaxation time, in addition to the ventricular isovolumetric relaxation time and the heart condition indication.

11. A method of monitoring a patient for diastolic heart failure with a cardiac device implanted in the patient, comprising:

obtaining with the implanted cardiac device a T wave ending time for a heart beat from an intracardiac electrogram;

obtaining with the implanted cardiac device a return to baseline time of left ventricle pressure for the heart beat from a left ventricle pressure sensor;

deriving a ventricular relaxation time for the heart beat from the T wave ending time and the return to baseline time;

evaluating diastolic heart failure from the derived ventricular relaxation time; and

adjusting a therapeutic action in response to the evaluation of diastolic heart failure.

12. The method of claim 11 wherein the diastolic heart failure evaluating step comprises evaluating diastolic heart failure from a prior progression of change in relaxation time, in addition to the calculated ventricular relaxation time.

13. The method of claim 11 further comprising:

detecting absence of a heart condition having a possible influence on the ventricular relaxation time, other than reduced ventricular compliance;

wherein the diastolic heart failure evaluating step is performed in response to the heart condition absence detecting step.

14. The method of claim 11 further comprising triggering the return to baseline time obtaining step from the T wave ending time obtaining step.

15. The method of claim 11 wherein the evaluating step comprises:

comparing the derived ventricular relaxation time to a threshold condition; and

indicating diastolic heart failure when the derived ventricular relaxation time deviates in a predetermined manner from the threshold condition.

16. The method of claim 11 further comprising:

acquiring an RVT-EGM measurement from the patient with the cardiac device, the T wave ending time being obtained from the RVT-EGM measurement; and

assigning a predetermined threshold value as the baseline.

17. An implantable cardiac device comprising:

means for obtaining a T wave ending time from an intracardiac electrogram;

means for obtaining a return to baseline time of left ventricle pressure from a left ventricle pressure sensor;

means for deriving a ventricular relaxation time from the T wave ending time and the return to baseline time; and

means for evaluating diastolic heart failure from the calculated ventricular relaxation time.

18. An implantable cardiac device comprising:

means for obtaining a waveform indicative of left ventricular pressure of the patient during an early part of isovolumetric relaxation, prior to a mitral valve opening;

means for determining a parameter of the waveform obtained during the early part of isovolumetric relaxation; and

means for calculating an indication of diastolic heart failure from the waveform parameter.